Back to Journals » Biologics: Targets and Therapy » Volume 11

Paradoxical SAPHO syndrome observed during anti-TNF-α therapy for Crohn's disease

Authors Amano H, Matsuda R, Shibata T, Takahashi D, Suzuki S

Received 11 February 2017

Accepted for publication 30 March 2017

Published 22 May 2017 Volume 2017:11 Pages 65—69

DOI https://doi.org/10.2147/BTT.S134508

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Doris Benbrook

Hitoshi Amano,1 Reikei Matsuda,1 Tomohiko Shibata,2 Daisuke Takahashi,1 Shinichiro Suzuki3

1Department of Gastroenterology, Fujisawa Shonandai Hospital, Fujisawa, 2Division of Rheumatology, Department of Internal Medicine, St Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, 3Department of Surgery, Fujisawa Shonandai Hospital, Fujisawa, Japan

Abstract: Currently, anti-TNFα antibodies are used to treat Crohn’s disease. We report on a 45-year-old Japanese female with Crohn’s disease developing SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome following exposure to the anti-TNFα antibody adalimumab. Initially, adalimumab induced remission, but the patient showed SAPHO syndrome 11 weeks following the start of adalimumab therapy for the first time. Cutaneous and articular involvement were exacerbating the condition, so adalimumab was discontinued and the patient was put on low-dose methotrexate to control her symptoms. To our knowledge, this is the first report of SAPHO syndrome occurring during anti-TNF therapy, which is thought to be a paradoxical response to adalimumab.

Keywords: anti-TNFα, adalimumab, paradoxical reaction, SAPHO syndrome, Crohn’s disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]